Shoreline Biome, a Farmington-based biotech startup, secured $1.1M in equity funding.
Backers included Connecticut Innovations and independent investors.
The company intends to use the funds to continue development of their novel kits, protocols, and software.
Founded in June 2015 by Tom Jarvie, CEO and Mark Driscoll, CSO, Shoreline Biome novel kits, protocols, and software used to identify and quantify the bacteria in the human microbiome. Its kits feature comprehensive lysis of even hard to crack microbes, simple workflow, and the ability to identify organisms down to the strain-level. The initial kits can be used on the Illumina and PacBio sequencing platforms.
The company, which is located at the UConn Technology Incubation Program on the UConn Health campus in Farmington, collaborates closely with faculty from The Jackson Laboratory for Genomic Medicine, Yale University, and UConn.
The financing follows several other achievements including winning a UConn Innovation Fund investment for the development of spore and cell lysis technology and a Phase I SBIR grant from the National Institute of Drug Abuse (NIDA), part of the NIH. The SBIR grant was funded to develop kits, methods, and software for high-resolution amplicon microbiome profiling. The project is a collaboration between Shoreline Biome, George Weinstock, PhD, Professor, and Evnin Family Chair and Director of Microbial Genomics at The Jackson Laboratory for Genomic Medicine and Dr. David Hafler, William S. and Lois Stiles Edgerly Professor of Neurology and Professor of Immunobiology; Chair, Department of Neurology of the Yale School of Medicine. Dr. Hafler is also the Neurologist-in-Chief, Yale New Haven Hospital.